Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

CD8(+) T cells restrict Yersinia pseudotuberculosis infection: bypass of anti-phagocytosis by targeting antigen-presenting cells.

Bergman MA, Loomis WP, Mecsas J, Starnbach MN, Isberg RR.

PLoS Pathog. 2009 Sep;5(9):e1000573. doi: 10.1371/journal.ppat.1000573. Epub 2009 Sep 4.

PMID:
19730693
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.

Zhang Y, Mena P, Romanov G, Lin JS, Smiley ST, Bliska JB.

Infect Immun. 2012 Jan;80(1):206-14. doi: 10.1128/IAI.05971-11. Epub 2011 Nov 7.

PMID:
22064714
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Attenuated Yersinia pseudotuberculosis carrier vaccine for simultaneous antigen-specific CD4 and CD8 T-cell induction.

Rüssmann H, Gerdemann U, Igwe EI, Panthel K, Heesemann J, Garbom S, Wolf-Watz H, Geginat G.

Infect Immun. 2003 Jun;71(6):3463-72.

PMID:
12761131
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Induction of CD8+ T cell responses by Yersinia vaccine carrier strains.

Wiedig CA, Kramer U, Garbom S, Wolf-Watz H, Autenrieth IB.

Vaccine. 2005 Oct 10;23(42):4984-98.

PMID:
15985316
[PubMed - indexed for MEDLINE]
5.
6.

Yersinia pseudotuberculosis inhibits Fc receptor-mediated phagocytosis in J774 cells.

Fällman M, Andersson K, Håkansson S, Magnusson KE, Stendahl O, Wolf-Watz H.

Infect Immun. 1995 Aug;63(8):3117-24.

PMID:
7622239
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Type III secretion decreases bacterial and host survival following phagocytosis of Yersinia pseudotuberculosis by macrophages.

Zhang Y, Murtha J, Roberts MA, Siegel RM, Bliska JB.

Infect Immun. 2008 Sep;76(9):4299-310. doi: 10.1128/IAI.00183-08. Epub 2008 Jun 30.

PMID:
18591234
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Coordinate involvement of invasin and Yop proteins in a Yersinia pseudotuberculosis-specific class I-restricted cytotoxic T cell-mediated response.

Falgarone G, Blanchard HS, Virecoulon F, Simonet M, Breban M.

J Immunol. 1999 Mar 1;162(5):2875-83.

PMID:
10072536
[PubMed - indexed for MEDLINE]
Free Article
9.

Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV.

Daniel C, Sebbane F, Poiret S, Goudercourt D, Dewulf J, Mullet C, Simonet M, Pot B.

Vaccine. 2009 Feb 18;27(8):1141-4. doi: 10.1016/j.vaccine.2008.12.022. Epub 2009 Jan 9.

PMID:
19135495
[PubMed - indexed for MEDLINE]
10.

Intranasal inoculation of mice with Yersinia pseudotuberculosis causes a lethal lung infection that is dependent on Yersinia outer proteins and PhoP.

Fisher ML, Castillo C, Mecsas J.

Infect Immun. 2007 Jan;75(1):429-42. Epub 2006 Oct 30.

PMID:
17074849
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Interleukin-10 induction is an important virulence function of the Yersinia pseudotuberculosis type III effector YopM.

McPhee JB, Mena P, Zhang Y, Bliska JB.

Infect Immun. 2012 Jul;80(7):2519-27. doi: 10.1128/IAI.06364-11. Epub 2012 Apr 30.

PMID:
22547545
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Innate immune recognition of Yersinia pseudotuberculosis type III secretion.

Auerbuch V, Golenbock DT, Isberg RR.

PLoS Pathog. 2009 Dec;5(12):e1000686. doi: 10.1371/journal.ppat.1000686. Epub 2009 Dec 4.

PMID:
19997504
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Yersinia enterocolitica Yop mutants as oral live carrier vaccines.

Leibiger R, Niedung K, Geginat G, Heesemann J, Trülzsch K.

Vaccine. 2008 Dec 2;26(51):6664-70. doi: 10.1016/j.vaccine.2008.09.020.

PMID:
18822332
[PubMed - indexed for MEDLINE]
15.

Susceptibility to Yersinia pseudotuberculosis infection is linked to the pattern of macrophage activation.

Tansini A, de Medeiros BM.

Scand J Immunol. 2009 Apr;69(4):310-8. doi: 10.1111/j.1365-3083.2008.02212.x.

PMID:
19284495
[PubMed - indexed for MEDLINE]
16.

Efficacy of an oral live vaccine for veterinary use against pseudotuberculosis.

Quintard B, Petit T, Ruvoen N, Carniel E, Demeure CE.

Comp Immunol Microbiol Infect Dis. 2010 Dec;33(6):e59-65. doi: 10.1016/j.cimid.2009.12.001. Epub 2010 Jan 19.

PMID:
20034670
[PubMed - indexed for MEDLINE]
17.

Role of YopK in Yersinia pseudotuberculosis resistance against polymorphonuclear leukocyte defense.

Thorslund SE, Ermert D, Fahlgren A, Erttmann SF, Nilsson K, Hosseinzadeh A, Urban CF, Fällman M.

Infect Immun. 2013 Jan;81(1):11-22. doi: 10.1128/IAI.00650-12. Epub 2012 Oct 22.

PMID:
23090955
[PubMed - indexed for MEDLINE]
Free PMC Article
18.
19.

Cell type-specific effects of Yersinia pseudotuberculosis virulence effectors.

Fahlgren A, Westermark L, Akopyan K, Fällman M.

Cell Microbiol. 2009 Dec;11(12):1750-67. doi: 10.1111/j.1462-5822.2009.01365.x. Epub 2009 Aug 4.

PMID:
19681909
[PubMed - indexed for MEDLINE]
20.

Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection.

Colmenares M, Kima PE, Samoff E, Soong L, McMahon-Pratt D.

Infect Immun. 2003 Jun;71(6):3172-82.

PMID:
12761096
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk